ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

DCBDC Board Ok’s New Initiative For Training

November 16, 1990

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

May 31, 2013

In Congress: Continuing Resolutions Keep Feds Running; Henney Nomination Stalled By Nickles

October 16, 1998

Program Announcement: Breast Cancer Research

May 28, 1993

Abbott To Supply Quest With Immunoassay Tests.

September 29, 2000